X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Biomedicines

期刊標題檢索 BIOMEDICINES 最新評論: I have submitted a lot, including some bad articles and articles that ... (2024-11-15)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Biomedicines]您好,您是該頁面的第 86284 位訪客。

期刊簡介
期刊名稱Biomedicines Biomedicines
LetPub Score
7.3
51 ratings
Rate

Reputation
8.3

Influence
6.1

Speed
9.7

期刊簡稱BIOMEDICINES
ISSN2227-9059
h-indexN.A.
CiteScore
CiteScoreSJRSNIPCiteScore Rank
5.200.9620.814
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Medicine (miscellaneous)
Q2103 / 398
Category: Medicine
Subcategory: General Biochemistry, Genetics and Molecular Biology
Q274 / 221

自引率 (2023-2024)5.10%自引率趨勢
掲載範囲
Biomedicines (ISSN 2227-9059; CODEN: BIOMID) is an international, scientific, open access journal on biomedicines published quarterly online by MDPI.
官方網站https://www.mdpi.com/journal/biomedicines
在線稿件提交
開放訪問Yes
出版商Multidisciplinary Digital Publishing Institute (MDPI)
主題領域Biochemistry, Genetics and Molecular Biology
出版國/地區SWITZERLAND
發行頻率
創刊年0
每年文章數3294每年文章數趨勢
黃金OA百分比99.65%
OA Related Info
APC: Yes( CHF2600; )
APC waiver:Check Notes
Other charges: No
Keywords: biological active substances、quality and safety of biological pharmaceutical products、gene therapy、challenges in administration of biomedicines、development of biomedicines、production of biomedicines
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
BIOCHEMISTRY & MOLECULAR BIOLOGYSCIEQ2104/313
MEDICINE, RESEARCH & EXPERIMENTALSCIEQ264/189
PHARMACOLOGY & PHARMACYSCIEQ185/354
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2227-9059%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: 8 Weeks
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【Biomedicines】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    EBioMedicineH-index: 37

    CiteScore: 17.70
    Current Research in Translational MedicineH-index: 54

    CiteScore: 7.00
    Life-BaselH-index: 0

    CiteScore: 4.30
    YALE JOURNAL OF BIOLOGY AND MEDICINEH-index: 0

    CiteScore: 5.00
    Biopreservation and BiobankingH-index: 0

    CiteScore: 3.30
    學科內最受檢索的期刊 頁面查看次數
    EBioMedicine220937
    Life-Basel42519
    Current Research in Translational Medicine13256
    Biopreservation and Biobanking10917
    YALE JOURNAL OF BIOLOGY AND MEDICINE10432
  •  

    Biomedicines Biomedicines
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [Biomedicines] 的評論撰寫評論
作者: 高天上圣


領域: 医学
審稿時間: 1.0 month(s)
結果: 拒稿


撰寫評論

2024-11-15 16:54:54 評論於
I have submitted a lot, including some bad articles and articles that were rejected by non-OA journals. However, all submissions to MDPI were rejected instantly. Sigh.
(0) 讚! | 高天上圣

作者: zyl1994


領域: 医学
審稿時間: 1.0 month(s)
結果: 修改後接受


撰寫評論

2022-06-13 16:51:04 評論於
It may be because you work in a hospital and have seen reports before that MDPI is not easily accepting submissions from domestic medical units. I submitted to a university, and I don't know any editors. Some were rejected immediately, while others were accepted after revisions. Overall, I feel that it is relatively formal.
(0) 讚! | zyl1994

作者: 猫猫小女子


領域: 生物学
審稿時間: 1.0 month(s)
結果: 修改後接受


撰寫評論

2021-08-21 11:54:37 評論於
When I submitted my first article, it was rejected. After making revisions, I submitted it again and it was rejected once more. I was not satisfied and added some experiments before submitting it again. Finally, it was accepted. Now, the impact factor of this journal has exceeded 6. I feel that it is becoming increasingly difficult to submit articles. I estimate that it may drop in the ranking next year, but I am optimistic about the potential increase in the impact factor.
(0) 讚! | 猫猫小女子

作者: 猫猫小女子


領域: 医学
審稿時間: 1.0 month(s)
結果: 待定&不明


撰寫評論

2021-03-20 05:18:56 評論於
It's not that I'm saying anything, I work in oncology. I submitted my paper to this journal unexpectedly, and it got published. I didn't intentionally aim for this journal, but the review process was very fast. There were two reviewers and one research editor, and they provided a lot of comments. The key point is that their feedback was very professional. I even suspected that my field might have ended up in the hands of these three individuals. One reviewer seemed like they were rejecting the paper, while the other two suggested major revisions. The editor ultimately decided on major revisions and requested additional experiments. After 20 days, I resubmitted the revised paper, and it underwent another round of major revisions, although the changes were not extensive. I don't think it can be considered as a major revision. I resubmitted it within 10 days, and I will receive the results in the next couple of days. Overall, I feel that this journal is quite professional. Once you see the reviewers' comments, you will understand. They pointed out everything that you might be afraid of being asked, which made me quite nervous. Although the publication fee is expensive, I still hope for acceptance. After all, the revisions were quite difficult. I will come back with good news if there is any, and if there is no news, it means bad news.
(16) 讚! | 猫猫小女子

作者: ritsu


領域: 医学
審稿時間: 1.0 month(s)
結果: 修改後接受


撰寫評論

2020-12-19 10:20:10 評論於
It was submitted as an solicit manuscript. The review comments were returned one month after submission. There were 3 reviewers. It was accepted one week after minor revision submitted. The IF is going to rise, with a high probability of reaching 5.5 next year.

(13) 讚! | ritsu

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [Biomedicines] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*